Niranthin
(Synonyms: 珠子草素) 目录号 : GC17997
Niranthin，一种具有广泛药理活性的木脂素。
Cas No.:50656-77-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 15.6 μM and 25.1 μM for inhibiting the secretion of HBsAg and HBeAg, respectively.
Niranthin is a natural lignin isolated from the genus Phyllanthus, with antiviral activities both in vitro and in vivo. Niranthin also exerts anti-inflammatory and anti-allodynic activities.
In Vitro: In human hepatoma cell line MS-G2 which synthesizes hepatitis B viral particles, Niranthin was screened among 25 pure compounds which were isolated from several phyllanthus species with the most potent anti-HBV activity (EC50= 33.6 μM) by effectively suppressing the expression of HBsAg and HBeAg, with the highest inhibition of 74.3% [1]. Besides, in human HBV-transfected liver cell line HepG2.2.15, Niranthin could significantly inhibit the secretion of HBsAg and HBeAg after treatment for 144 h, with the IC50 values of 15.6 μM and 25.1 μM, respectively [2].
In Vivo: In duck hepatitis B virus (DHBV) infected ducks, intragastric administration of Niranthin could significantly decrease the plasma DHBV DNA levels, with the mean inhibition percentage of 70.72%, 75.23%, and 90.87% at the dose of 25, 50, and 100 mg/kg/day, respectively. Niranthin could also significantly inhibit the serum HBsAg, HBeAg, ALT, and AST levels [2].
Clinical trial: no data available.
References:
[1] Huang R, Huang Y, Ou J, et al. Screening of 25 compounds isolated from Phyllanthus species for anti-human hepatitis B virus in vitro[J]. Phytotherapy Research, 2003, 17(5): 449-453.
[2] Liu S, Wei W, Li Y, et al. In vitro and in vivo anti-hepatitis B virus activities of the lignan nirtetralin B isolated from Phyllanthus niruri L.[J]. Journal of Ethnopharmacology, 2014, 157(2): 1061-1067.
| Cas No. | 50656-77-4 | SDF | |
| 别名 | 珠子草素 | ||
| 化学名 | rel-6-[(2R,3R)-4-(3,4-dimethoxyphenyl)-2,3-bis(methoxymethyl)butyl]-4-methoxy-1,3-benzodioxole | ||
| Canonical SMILES | COC1=CC(C[C@@H](COC)[C@H](COC)CC2=CC(OC)=C(OC)C=C2)=CC3=C1OCO3 | ||
| 分子式 | C24H32O7 | 分子量 | 432.5 |
| 溶解度 | DMF: 15 mg/ml,DMSO: 10 mg/ml,Ethanol: 5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3121 mL | 11.5607 mL | 23.1214 mL |
| 5 mM | 0.4624 mL | 2.3121 mL | 4.6243 mL |
| 10 mM | 0.2312 mL | 1.1561 mL | 2.3121 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet